The 3 Lies of Reven Pharmaceuticals

Investigation: Securities Fraud Enforcement A federal appeals court has kept an asset freeze in place against the drug developer and its three principals, citing preliminary evidence of understated executive pay, an audit that never began, and a fraud lawsuit thatβ¦








